CN111979265B - Construction method of spontaneous squamous cell lung carcinoma mouse model - Google Patents
Construction method of spontaneous squamous cell lung carcinoma mouse model Download PDFInfo
- Publication number
- CN111979265B CN111979265B CN202010690583.0A CN202010690583A CN111979265B CN 111979265 B CN111979265 B CN 111979265B CN 202010690583 A CN202010690583 A CN 202010690583A CN 111979265 B CN111979265 B CN 111979265B
- Authority
- CN
- China
- Prior art keywords
- yap1
- mouse
- trp53
- conditional
- knock
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010276 construction Methods 0.000 title claims abstract description 26
- 238000010172 mouse model Methods 0.000 title claims abstract description 17
- 201000005243 lung squamous cell carcinoma Diseases 0.000 title abstract description 17
- 230000002269 spontaneous effect Effects 0.000 title abstract description 16
- 101150020580 yap1 gene Proteins 0.000 claims abstract description 56
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 45
- 230000008685 targeting Effects 0.000 claims abstract description 36
- 241000699670 Mus sp. Species 0.000 claims abstract description 20
- 239000003550 marker Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 101100319886 Caenorhabditis elegans yap-1 gene Proteins 0.000 claims abstract description 6
- 101100319891 Mus musculus Yap1 gene Proteins 0.000 claims description 31
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 claims description 14
- 102000047087 human SFTPC Human genes 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000000137 annealing Methods 0.000 claims description 9
- 210000002459 blastocyst Anatomy 0.000 claims description 9
- 238000004925 denaturation Methods 0.000 claims description 9
- 230000036425 denaturation Effects 0.000 claims description 9
- 238000012257 pre-denaturation Methods 0.000 claims description 9
- 238000011813 knockout mouse model Methods 0.000 claims description 8
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims description 7
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 230000013011 mating Effects 0.000 claims description 6
- 238000012795 verification Methods 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 101150080773 tap-1 gene Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 5
- 230000005740 tumor formation Effects 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000011830 transgenic mouse model Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 11
- 238000001514 detection method Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 238000001976 enzyme digestion Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004952 blastocoel Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241001244729 Apalis Species 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 101100055261 Mus musculus Aldh2 gene Proteins 0.000 description 1
- 101100462520 Mus musculus Tp53 gene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a construction method of a spontaneous squamous cell lung carcinoma mouse model, and relates to the technical field of mouse model construction; the invention constructs a mouse with conditional Yap1 knock-in (Yap 1) by designing a targeting vector for the conditional Yap1 knock-inKI) Because of the cancer promotion effect of Yap1, the spontaneous lung squamous cell carcinoma has the characteristic of rapid tumor formation, then a negative selection marker (DTA) and a positive selection marker (Neo) are introduced into a targeting vector according to the standard design of a transgenic mouse, so that positive clones can be conveniently and rapidly obtained, and finally the Trp53 gene is utilized to knock out the mouse and the Yap1KIThe mice are hybridized to obtain the Yap1KI/Trp53KOAnd (5) finishing the construction of the spontaneous squamous cell lung carcinoma mouse model.
Description
Technical Field
The invention belongs to the technical field of mouse model construction, and particularly relates to a construction method of a spontaneous squamous cell lung carcinoma mouse model.
Background
Lung cancer is the first malignant tumor in human at present, and the morbidity and mortality of lung cancer are the first. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer patients; in NSCLC, 60-80% of lung adenocarcinoma and 20-40% of lung squamous cell carcinoma are present, and the animal model is essential for the treatment and mechanism research of lung cancer, especially lung squamous cell carcinoma. However, the existing lung squamous carcinoma mouse model has a plurality of obvious defects, mainly: (1) spontaneous tumor formation is extremely slow, often requiring months or even 1 year, and is very unfavorable for experimental research; (2) the pathological type in the spontaneous tumor tissue is not pure, and a plurality of pathological subtypes exist in the same tumor tissue; (3) since the knockout of the oncogene does not have the specificity of the development of squamous cell lung carcinoma, etc., the research of animal models into which oncogenes are introduced is lacking. Therefore, a more scientific and reasonable spontaneous lung squamous carcinoma mouse model is urgently needed.
Disclosure of Invention
In view of the above, the invention aims to provide a method for constructing a spontaneous squamous cell lung carcinoma mouse model, which is simple and has the characteristic of rapid tumor formation.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a construction method of a spontaneous squamous cell lung carcinoma mouse model, which comprises the following steps: (1) construction of mouse Yap1 with conditional Yap1 knockin Using the targeting vector for conditional Yap1 knockinKI;
(2) Mouse Yap1 into which the conditional Yap1 was knockedKITrp53 gene knockout mouse Trp53KOHybridizing to obtain Yap1KI/Trp53KOA mouse.
Preferably, the conditional Yap1 knock-in targeting vector in step (1) further comprises a negative selection marker DTA and a positive selection marker Neo.
Preferably, the targeting vector for the conditional Yap1 knock-in takes KI431-basic vector as a basic vector, and also comprises a mouse Yap1 gene, a human SP-C promoter and a mouse ROSA26 gene which are connected in sequence; the nucleotide sequence of the SP-C promoter is shown as SEQ ID NO. 1.
Preferably, the point mutation site of the mouse Yap1 gene is TCC 336 GCC.
Preferably, the construction method of the conditional Yap1 knock-in targeting vector comprises the following steps: (a) introducing point mutation into TCC 336GCC site of the mouse Yap1 gene to obtain a mutant Yap1 gene;
(b) connecting the SP-C promoter from Human with the mutant Yap1 gene to obtain a Human SP-C promoter-mutant mouseYap1 CDS-ployA box;
(c) cloning the Human SP-C promoter-mutant mouse Yap1 CDS-ployA box into an intron1 of ROSA26 in the opposite direction to obtain the Human SP-C promoter-mutant mouse Yap1 CDS;
(d) the sequence of the Human SP-C promoter-mutant mouse Yap1 CDS was ligated into the KpnI/PmlI cleavage backbone of the base vector.
Preferably, the conditional Yap1 knock-in targeting vector is knocked into a mouse blastocyst in step (1) by using an ES targeting method.
Preferably, the hybridization in the step (2) is to select the mouse Yap1 with the conditional Yap1 knock-in functionKIIs homozygote of (2) with Trp53KOHomozygotes from knockout mice were mated with cages.
Preferably, the pups obtained after mating with the cages are subjected to PCR verification.
Preferably, the PCR verified primers comprise primers Neo-del-F, Neo-del-R and WT-F for detecting Yap 1; primers Trp53-F1, Trp53-R1 and Trp53-F3 for detecting Trp 53;
the nucleotide sequence of the Neo-del-F is shown as SEQ ID NO.2, the nucleotide sequence of the Neo-del-R is shown as SEQ ID NO.3, and the nucleotide sequence of the WT-F is shown as SEQ ID NO. 7;
the nucleotide sequence of Trp53-F1 is shown as SEQ ID NO.4, the nucleotide sequence of Trp53-R1 is shown as SEQ ID NO.5, and the nucleotide sequence of Trp53-F3 is shown as SEQ ID NO. 6.
Preferably, the PCR verification procedure includes: the PCR program for detecting Tap1 by using primers Neo-del-F, Neo-del-R and WT-F comprises: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 64 ℃ for 35s, extension at 72 ℃ for 35s, and 33 cycles; extending for 5min at 72 ℃;
the PCR program for detecting Trp53 by using the primers Trp53-F1 and Trp53-R1 comprises the following steps: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 70 ℃ for 30s, and extension at 72 ℃ for 50s for 35 cycles; extending for 10min at 72 ℃;
the PCR program for detecting Trp53 by using the primers Trp53-F3 and Trp53-R1 comprises the following steps: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 70 ℃ for 30s, and extension at 72 ℃ for 50s, for 33 cycles; extension at 72 ℃ for 10 min.
The invention provides a construction method of a spontaneous squamous cell lung carcinoma mouse model, which is characterized in that a conditional Yap1 knock-in mouse (Yap 1) is constructed by designing a targeting vector for conditional Yap1 knock-inKI) Because of the cancer promotion effect of Yap1, the spontaneous lung squamous cell carcinoma has the characteristic of rapid tumor formation, then a negative selection marker (DTA) and a positive selection marker (Neo) are introduced into a targeting vector according to the standard design of a transgenic mouse, so that positive clones can be conveniently and rapidly obtained, and finally the Trp53 gene is utilized to knock out the mouse and the Yap1KIThe mice are hybridized to obtain the Yap1KI/Trp53KOAnd (5) finishing the construction of the spontaneous squamous cell lung carcinoma mouse model.
Drawings
FIG. 1 is a conditional Yap1 typing construction strategy;
FIG. 2 shows the construction process of Yap1 knock-in mice;
FIG. 3 is a targeting vector plasmid map;
FIG. 4 is a graph of the results of targeted ES clones;
FIG. 5 shows the selection of regions for southern Blots;
FIG. 6 is a graph showing southern blot results;
FIG. 7 is a sequencing diagram of the Yap1 mutant;
FIG. 8 is a graph showing the results of HE staining, in which Yap1 is shown in the order from left to rightKITrp53KO(pulmonary trachea), Yap1KITrp53KO(lung lobes) and control);
FIG. 9 shows immunohistochemical results, wherein KI67, P63 and Yap1 are represented in order from left to right;
fig. 10 shows the results of a CT experiment on lung volumes.
Detailed Description
The invention provides a construction method of a spontaneous squamous cell lung carcinoma mouse model, which comprises the following steps:
(1) construction of mouse Yap1 with conditional Yap1 knockin Using the targeting vector for conditional Yap1 knockinKI;
(2) Mouse Yap1 into which the conditional Yap1 was knockedKIHybridizing with Trp53 knockout mice to obtain Yap1KI/Trp53KOA mouse.
The invention utilizes the targeting vector of the conditional Yap1 knock-in to construct the mouse Yap1 of the conditional Yap1 knock-inKI. The conditional Yap1 knock-in targeting vector of the invention preferably further comprises a negative selection marker D TA and a positive selection marker Neo. The targeting vector for the conditional Yap1 knock-in is preferably a K I431-basic vector-based vector, and further comprises a mouse Yap1 gene, a human SP-C promoter and a mouse ROSA26 gene which are sequentially connected; the nucleotide sequence of the SP-C promoter is shown as SE Q ID NO.1 (amplification primers CF and CR, CF (SEQ ID NO.8) -GGCTGTTG CGCGGGCTCCAT; CR (SEQ ID NO.9) -TTAAAGTTAGTAGCGTCGACC ACGTGACTAG). The mouse Yap1 gene is positioned on a mouse chromosome 9, and the NCBI reference sequence: NM-001171147.1 (amplification primers AF/AR and BF/B, AF (SEQ ID N O.10) -GCAGCCTGCACCTGAGGATAATCGATCTATAACCACGTGAGAAA GCTTTCT, AR (SEQ ID NO.11) -TCCACAGCATGTTCGAGCTCACGCC TCTCCAGCCTCCCTGCAGCTG, BF (SEQ ID NO.12) -CAGCTGCAGGG AGGCTGGAGAGGCGTGAGCTCGAACATGCTGTGGA and BR (SEQ ID NO.13) -ATGGAGCCCGCGCAACAGCCGCC), when the mouse Yap1 gene is knocked in, point mutation is preferably introduced into the S112A site (336 TCC GCC) of the mouse Yap1 geneAnd the point mutation is to mutate TCC into GCC. The mouse ROSA26 gene is positioned on a mouse chromosome 6, and the NCBI reference sequence: NR _ 027008.1.
The construction method of the conditional Yap1 knock-in targeting vector is shown in FIG. 1, and preferably comprises the following steps:
(a) introducing point mutation into S112A site of a mouse Yap1 gene to obtain a mutant Yap1 gene, wherein the point mutation is to mutate TCC into GCC;
(b) connecting the SP-C promoter from Human with the mutant Yap1 gene to obtain a Human SP-C promoter-mutant mouseYap1 CDS-ployA box;
(c) cloning the Human SP-C promoter-mutant mouse Yap1 CDS-ployA box into an intron1 of ROSA26 in the opposite direction to obtain the Human SP-C promoter-mutant mouse Yap1 CDS;
(d) the sequence of the Human SP-C promoter-mutant mouse Yap1 CDS was ligated into the KpnI/PmlI cleavage backbone of the base vector.
The S112A (TCC mutated into GCC) mutant (GenBank accession number: NM-001171147.1, Ensembl: ENSMUSG00000053110) of the mouse Yap1 gene has nuclear transcription activity, can play a biological function when entering the nucleus, and can realize fixed-point insertion when being inserted into an intron1 of a Rosa26 gene (GenBank accession number: NR-027008.1, Ensembl: ENSMUSG 00000086429). In the present invention, the KI sequence is preferably ligated in reverse orientation to ROSA26 (forward) arm, i.e., it can be cloned in reverse orientation to ROSA26 intron 1.
The conditional Yap1 knock-in targeting vector is knocked into a mouse blastocyst preferably by an ES targeting method, and before the ES targeting, the conditional Yap1 knock-in targeting vector preferably further comprises amplifying a mouse genome segment containing Homology Arms (HAs) from a BAC clone by using high fidelity Taq, and then assembling the amplified segment together with a recombination site and a selection marker downstream of the amplified segment into a targeting vector to form the targeting vector shown in FIG. 3, wherein the positive selection marker Neo is flanked by an SDA (self-deletion anchor) site, and the negative selection marker DTA is used for negative selection. The invention preferably uses BAC clones from the C57BL/6 library as templates to generate homology arms by PCR. The method of targeting ES in the present invention is not particularly limited, and a conventional ES targeting method in the art may be used.
Mouse Yap1 with conditional Yap1 knock-inKIThen, the invention uses the mouse Yap1 into which the conditional Yap1 is knockedKIHybridizing with Trp53 knockout mice to obtain Yap1KI/Trp53KOA mouse. The Trp53 gene knockout mouse is a model mouse purchased from Spacerola Biotech limited company, and can be obtained by self-making or purchasing a commercially available product, and when the Trp53 gene knockout mouse is self-made, the sgRNA is preferably designed by adopting a CRISPR/Cas9 technology, and the Trp53 gene knockout mouse is obtained by applying a high-flux electrotransformation zygote mode.
The hybridization according to the invention is preferably a mouse Yap1 which selects the conditional Yap1 knock-inKIThe homozygote of (4) and the homozygote of a Trp53 knockout mouse (Trp 53)KO) Mating with cage, and performing mating with Trp53KOAs male parent, Yap1KIIs used as a female parent; or Yap1KIAs male parent, Trp53KOThe number ratio of the male parent to the female parent is preferably 1: 2. According to the invention, the young animals obtained after mating with the cage are preferably subjected to PCR verification, and the PCR verification primer preferably comprises: detecting primers Neo-del-F, Neo-del-R and WT-F of Yap 1; primers Trp53-F1, Trp53-R1 and Trp53-F3 for detecting Trp 53;
the nucleotide sequence of Neo-del-F is shown as SEQ ID NO.2 (5'-AGTGGTCTTCGTTCCCTGGACT-3'), the nucleotide sequence of Neo-del-R is shown as SEQ ID NO.3 (5'-CAAGAGACCACATGGCAGGAAG-3'), and the nucleotide sequence of WT-F is shown as SEQ ID NO.7 (5'-TTGAAGCATTCCCTAATGAGCCAC-3');
the nucleotide sequence of Trp53-F1 is shown in SEQ ID NO.4 (5'-GCTTTCCCACCCTCGCATAAG-3'), the nucleotide sequence of Trp53-R1 is shown in SEQ ID NO.5 (5'-TTCACTACAAAGGCTGAGCTGGAG-3'), and the nucleotide sequence of Trp53-F3 is shown in SEQ ID NO.6 (5'-CCATAAGACAGGTGCTCCTCCAC-3').
The PCR verification procedure of the present invention preferably comprises: the PCR program for detecting Tap1 by using primers Neo-del-F, Neo-del-R and WT-F comprises: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 64 ℃ for 35s, extension at 72 ℃ for 35s, and 33 cycles; extending for 5min at 72 ℃;
the PCR program for detecting Trp53 by using the primers Trp53-F1 and Trp53-R1 comprises the following steps: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 70 ℃ for 30s, and extension at 72 ℃ for 50s for 35 cycles; extending for 10min at 72 ℃;
the PCR program for detecting Trp53 by using the primers Trp53-F3 and Trp53-R1 comprises the following steps: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 70 ℃ for 30s, and extension at 72 ℃ for 50s, for 33 cycles; extension at 72 ℃ for 10 min.
The following examples are provided to illustrate the method for constructing the idiopathic squamous cell lung carcinoma mouse model of the present invention, but they should not be construed as limiting the scope of the present invention.
Example 1
Firstly, designing and constructing a conditional Yap1 knock-in targeting vector: a mouse Yap1 conditional knock-in model was created in C57BL/6 mice. (see FIGS. 1 and 2)
1. Vector construction:
(1) ordering BAC, and simultaneously preparing primers required by vector construction; (2) extracting BAC by shaking bacteria, and preparing a basic vector plasmid (KI431-basic vector); (3) PCR amplifying a target fragment Yap1 from BAC DNA, detecting an amplification product through electrophoresis, cutting gel and recovering the target fragment; (4) the target fragment is connected with a basic vector (basic vector is cut by pmlI and KpnI); (5) the ligation products are transformed to be competent and plated overnight for culture; (6) selecting a single colony, and screening positive clones by colony PCR; (7) carrying out enzyme digestion identification on colony PCR positive clone small extract plasmid; (8) sequencing and verifying the positive clone identified by enzyme digestion; (9) sequencing is correct, and the target fragment is successfully connected into a basic carrier; (10) preserving positive clone strains, and connecting plasmids with other fragments; (11) the ligation of each target fragment was completed to obtain the final vector (see Targeting vector in FIG. 1).
2. Plasmid preparation:
(1) preparing reagents and articles required by plasmid preparation; (2) transforming the carrier plasmid into escherichia coli; (3) shaking the bacteria, and then extracting plasmids by using a kit; (4) restriction enzyme digestion with enzymes to verify plasmids (ApaLI, DrdI, NcoI, Agel/Scal, Ahd1, Notl); (5) carrying out plasmid linearization by using NotI single enzyme digestion; (6) recovering the linearized plasmid; (7) verifying the recovered linearized plasmid by AhdI single enzyme digestion; (8) the linearized vector plasmid is used for subsequent ES cell targeting.
ES targeting-electrotransfer:
(1) preparing reagents and articles required by electrotransformation; (2) culturing ES cells (containing ROSA26 Wildtype allel); (3) pancreatin digestion and cell count (6X 10)6cells), determining that the cell mass is sufficient for electroporation; (4) centrifuging to collect cells, adding an electrotransfer buffer solution and linearized plasmid DNA, carrying out ice bath for a moment, and adding the mixture into an electrotransfer cup for electrotransfer; (5) after electrotransfer, the cells are immediately inoculated in an ES culture medium in an ice bath; (6) culturing overnight, adding medicine the next day, and screening for drug resistance (screening Neo and DTA, and finally obtaining Targeted allele); (7) continuing culturing, and selecting the monoclonal antibody to be cloned in a 96-well plate after the cells grow stably; (8) transferring the 96-well plate ES cells to a new 96-well plate, and carrying out subculture; (9) after the cells grow stably, the cells of a 96-well plate are subjected to PCR detection and primary targeting screening; at the same time, the backup plates were stored at-80 ℃.
The linearized vector was delivered to ES cells (C57BL/6) by electroporation, followed by drug selection, PCR screening and southern blot confirmation. After 91 resistant clones were obtained, there were 7 potential targeting clones, of which 6 were amplified for southern blot (fig. 4), and samples 1F2, 1D4, 1B5, 1G6, 1H5, 1D8, and 1D9 were confirmed as potential targeting ES clones.
The region shown in FIG. 5 was selected for southern Blots and the expected fragment size was:
Neo Probe(containing 5’HA)–9.7Kbp–HindIII
neo Probe (cloning 3' HA) -12.7 Kbp-Kpn I, and the results are shown in FIG. 6, and the above 6 clones were correct.
ES targeting-PCR screening:
(1) designing and preparing primers, and carrying out primer test to select the optimal primer; (2) the mixed solution of SDS lysate and proteinase K is used for lysing the ES cells of the 96-pore plate and is lysed overnight; (3) precipitating the genome DNA by using a mixed solution of anhydrous glacial ethanol and sodium chloride the next day; (4) washing the precipitate with 70% ethanol, removing residual ethanol, adding mixed solution of RNAaseA and water for injection, sealing the incubator at 37 deg.C overnight, and using as PCR template; (5) preparing a 96-hole PCR plate, and carrying out PCR amplification and electrophoresis detection; (6) and (5) completing electrophoresis and recording the detection result.
Wherein the 3' arm PCR primer:
P1(SEQ ID NO.14):TCGACTAGAGCTTGCGGAACCCT;
P2(SEQ ID NO.15):AAGACACCAGTTTCAGCCCAAGTTC;
neo PCR primers:
P1(SEQ ID NO.14):TCGACTAGAGCTTGCGGAACCCT;
P5(SEQ ID NO.16):CAAGAGACCACATGGCAGGAAG;
KI PCR primers:
P3(SEQ ID NO.17):CAAAGCTGAAAGTCAAGTCTGCAG;
P4(SEQ ID NO.18):ACCCATGGTGAGAAGTGCAGATGG;
sequencing primer (SEQ ID NO. 19): CTCTTCAATGCCGTCATGAAATG are provided.
ES targeting-cell resuscitation passage:
(1) preparing reagents and articles required by cell resuscitation; (2) taking out the backup plate frozen at-80 ℃; (3) passaging PCR positive clones from 96-well plates to 12-well plates; (4) after the cells in the 12-hole plate grow stably, transferring the cells to a culture dish of 6 cm; (5) then transferring the cells of the 6cm culture dish to a 10cm culture dish; (6) after the cells grow stably, digesting, centrifugally collecting the cells, and freezing and storing part of the cells; a portion was sent for Southern analysis.
ES targeting-Southern Blot:
(1) designing an enzyme digestion scheme and a probe, and preparing required reagents and articles; (2) preparing a digoxin labeled probe (SEQ ID NO. 20: aaggcgatagaaggcgatgcgctgcgaatcgggagcggcgataccgtaaagcacgaggaagcggtcagcccattcgccgccaagctcttcagcaatatcacgggtagccaacgctatgtcctgatagcggtccgccacacccagccggccacagtcgatgaatccagaaaagcggccattttccaccatgatattcggcaagcaggcatcgccatgggtcacgacgagatcatcgccgtcgggcatgcgcgccttgagcctggcgaacagttcggctggcgcgagcccctgatgctcttcgtccagatcatcctgatcgacaagaccggcttccatccgagtacgtgctcgctcgatgcgatgtttcgcttggtggtcgaatgggcaggtagccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcaggagcaaggtgagatga) by a PCR method; (3) extracting ES cell genome DNA; (4) carrying out genome DNA enzyme digestion (BamHI and EcorV), and carrying out electrophoretic separation on enzyme digestion products; (5) transferring the electrophoresis gel to a nylon membrane, and transferring the DNA on the gel to the nylon membrane; (6) fixing a nylon membrane by ultraviolet crosslinking; (7) pre-hybridizing DNA; (8) after the prehybridization is finished, hybridizing overnight; (9) after hybridization, membrane washing and blocking are carried out; (10) adding antibody for incubation (Anti-Digoxigenin-AP, Fab fragments from sheet (Roche 11093274910)), washing with washing buffer, and adding detection buffer for equilibration; (11) putting the membrane into a substrate color development solution, and developing in a dark place; (12) and (4) finishing the color development, washing with a membrane washing buffer solution, and observing the result.
7. And (3) injecting blastocysts:
(1) obtaining blastocysts from the uterus of donor female mice 3.5 days after mating; (2) installing microinjection equipment, and preparing required reagents and articles; (3) selecting blastocysts with good shapes and moderate development states, and transferring the blastocysts into a culture medium of an injection dish; (4) transferring the ES to be injected into a cell culture medium of an injection dish, and uniformly arranging the ES to be injected into the cell culture medium with moderate density; (5) sucking ES cells into an injection needle, and injecting the ES cells into a blastocoel one by one; (6) after injection was complete, the ES cells were visualized within the blastocoel.
8. Preparing a surrogate mouse and transplanting an embryo:
(1) selecting a female mouse with the proper age and ligating a male mouse to be combined into a cage, and obtaining a surrogate female mouse; (2) transplanting the blastocyst injected with the ES cell into the uterus of a surrogate mother mouse; (3) putting the surrogate mother mouse into a clean cage box, preserving heat, and putting the surrogate mother mouse back to a cage frame for feeding after the surrogate mother mouse is clear; (4) completing blastocyst transplantation and allowing the chimeric mouse to be born; (5) chimeras (Targeted allole) were numbered 1 week after birth and caged 3 weeks later.
F1 mouse reproduction:
(1) male chimeras grow full for 8 weeks and are caged with 8-week-old female mice (B6 or Flp/Cre tool mice); (2) placing the young born baby into a new cage box, and numbering; (3) performing primary identification by cutting the toes of the mice at the age of about 1 week and performing detection PCR (the primers are shown as SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO. 7); (4) keeping the positive mice for the primary identification, cutting the mouse tails after about 2 weeks of age, sending to a test PCR, and carrying out secondary identification; (5) positive mice were identified by 2 PCRs as correctly targeted heterozygote mice (constitutive KI allele with neo deletion).
F1 mouse identification:
(1) extracting genome DNA, cracking a sample overnight by using a Triton X-100 and protease mixture lysate; (2) on the next day, protease is inactivated at high temperature, and the supernatant is collected by centrifugation and used as a PCR template; (3) PCR amplification and electrophoresis detection; (4) record the positive sample number.
Trp53 knockouts (Trp 53)KO) Establishment of mice of (1), creation of a mouse Trp53 conditional knock-out model in C57BL/6 mice
1) Subsequent studies were performed using Trp53 knockout mice purchased from seiko biotechnology limited;
2) trp53KOThe male and female of the mouse are separately raised for one week, and the environment is familiar;
3) trp53KOMouse sex cage (Henan: 1)&♀:2);
4) Numbering postnatal cubs, cutting toes of mice to extract genome DNA, inactivating protease at high temperature, centrifuging and collecting supernatant serving as a PCR template; then detecting by PCR amplification and electrophoresis, and recording the experimental result, wherein the young mouse is F2;
5) F is to be2The mice are mated in the same cage (sex: 1)&Male parent: 2) DNA extraction, PCR amplification and electrophoresis detection are carried out in the same way, the experimental result is recorded, and the young mouse is marked as F3;
Yap1 knock-in Trp53 knock-out (Yap 1)KI/Trp53KO) Mouse construction of
1) And selecting a mouse homozygous from Yap1 knock-in mice and mice homozygous from Trp53 knock-out mice to mate with a cage (male: 1 &: 2) (ii) a
2) Numbering postnatal cubs, cutting toes of mice to extract genome DNA, inactivating protease at high temperature, centrifuging and collecting supernatant as a PCR template; then PCR amplification and electrophoresis detection are carried out, and the experimental result is recorded.
HE staining
The lung trachea and lung lobes were extracted and subjected to HE staining, and the results are shown in FIG. 8, Yap1KI/Trp53KOObvious cancer nests appear in both the trachea and the lobes of the lungs of the group, and the cancer nests are large. Description of Yap1KI/Trp53KOMice have spontaneously developed tumors.
14. Immunohistochemistry
The results of immunohistochemical analysis using rabbit antibodies are shown in FIG. 9, where KI67, P63, and Yap1 are all in Yap1KI/Trp53KOHigh expression in the mouse lung.
CT analysis
The lung volume of the mice was analyzed by CT, and the results are shown in FIG. 10, Yap1KI/Trp53KOThe lung volume of the mouse is obviously higher than that of the wild mouse, which shows that Yap1KI/Trp53KOThe lung tissue of the mice proliferated significantly compared to wild-type mice.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> second subsidiary hospital of China civil liberation army, military and medical university
<120> construction method of spontaneous squamous cell lung carcinoma mouse model
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 3722
<212> DNA
<213> Homo sapiens
<400> 1
actagtgctg cctgggcttc tagtcttgtg ctttttgcac accagtccag ggaacgaaga 60
ccactggctt taagatgctt ccccagctgt ccccagactc tgccagcagg ggattctctg 120
gtctgagctt aagttgtgtt ctcccagcca gggatgcccc tgccctttga tgtctccttg 180
ctgccacaca tttagccgcc ctccccatgc cagcttgggg ggagggaagc agtgagggta 240
gggaggtggc tggggcagct gggcaactgt ccccacccgt ccctggcacg gctctgccca 300
gtacacaaag agcaaagtga atcttgtccc cacccctgca gctgaggggc tggaggagga 360
aacggggagg cccacacaga aggggtggcc accgtggggc tgtccatcac tcagggctct 420
cagagggagt caacccagaa acagacaaag agggtgagtc tgggctgtgt tcttagctag 480
tgagaggtcc cctagaggat gaagtagatg atgctaatga ggatgactgg atgtcacacc 540
catgatgcta ttaggtcctc ataatagcat agtgaggtgg acagctagta cctgacccat 600
ctcacagatg aacatactaa tgcctaacaa agcagaacga ctcacgctgg gtcccagagc 660
tggccagtgg aagcactgag acctccacat actgaaggca tggactattg accgctgttg 720
gtattggtct catcattgac tatcattaag tgttggctgt ttgcatgctt cctgcccagt 780
ggcaggttca aagaagcccg caggaagcgt gctcctttct ttcccagggc ccgcaattgg 840
gctggaagat agagcaacaa aaagcgccca tgtaactcat gggaacattc atgtgtgctg 900
aatggcaggt gaaggtgcca cagagaggct gaggatttca gagggcacca tgaactggag 960
tgaggtcgca gagcaggtgc cattggctct tggcctgttt gggtgggtgg cattcagaga 1020
ggtggaaggt cagatgcact gttcacgcct gtaatctcag cactttggaa ggccaaggta 1080
ggaggatcac acgaggccag gagatcaacg ctgcagtgag ctatgaagct gtgattgcac 1140
cactgcactg cagcttgggt aacagagtga gaccctgtct ctaaataatt aaataaataa 1200
aataaaaata aaaccggaga agtggagagg gattggaggt gggctttcac agagggagaa 1260
acggcttaag tacaggccaa aaagtgagaa ggctgcagac agggctggta gggggagggg 1320
gaaatttggc acacccagct aaaggtcctt ctgtgtctcc ttctccaagg aacccaagac 1380
cttcacttgg ttggtgtgag cactccagga ggcaggcacc ctccctcagc cctcaagcaa 1440
gcaaaaatgg gtttaaaaaa agaaggagaa gaagcagcag cagcagccgc cacagagctt 1500
gtgacagcta cagcctaagg gcaacaggca ggggagacca aggaccagaa agagcagagg 1560
ctttttcaaa gaaagagatc cctctcccag cacccagcga tggcggcaaa ccccacccac 1620
agtgcctgct aagaacaagt cccacgtgag aacaacatgg ccccccgaga tgcccacagg 1680
gaccccgaga tgcctgcagt gcttggctct cccgctggcc agctgcccac ctggctcagg 1740
cccagtactc gtgagtcagc cgatcaatcc caatgttgcc aggatgatgg gggcgggagt 1800
aagggccctg ggggagggca ggggtgggca ctgcaggcga gctgtctccc acatctggca 1860
cctgcacaca gctgaggccg agctgagagg atgcttctgt gggctccccc tcctcccggc 1920
acccctcccc tcctttcact gtcctaggac actctctggc tgctggagtc ttaggcaaat 1980
atttaaaggg gcagcaaggg ggtgaggagg gtggtgggag caaacacttc cctccctttc 2040
ttcctccctg cgcttctcag gggctctcag ttcagatgcc atgctgttat gcaaccttgg 2100
ggctgaaggc cctccagatg gagaggggga caggggaacc tgccagctca tgaccgaagg 2160
gcagggccca ggtgggaggg ggctggggca ggggacagga actggggtgg catgttaaag 2220
gacaggaggc tggttgggca tggtggctca cacctgtaat cctagcactt taggaggccg 2280
agatcacttg agcccaggag ttcgagacca gcctgggcaa catggtgaaa actcatctct 2340
ataaaacaag caaaaattag ctgggcacaa tggcatgcac tggtagtccc agctacttgg 2400
gatgctgagg tgtgaggatc accggagtcc aggaggtcaa cgctgcagtg agcagtgatc 2460
tcgctactgc atgccagcct gggtgataaa gtgagaccct gtctcacaac aaaacaaaac 2520
aaaacaaaac aaaaggatag gaggttaagg gagcgagccc aggcctggac tctgccacag 2580
tcacctgagt ttagaggtga agggacttta gagaccacct ggcccaagga gtgaaaggga 2640
acctgagaga aagggtgagc cagcccaaag tcattggcag atttgacctc gtaaatacat 2700
agagatggct ttgggaaggc actaggaaag acagagaaaa gagaaggaga cagtcctcaa 2760
agctgatcgt atttgggtga gtattattct cagggcaaat ttaggatcag aggatgcaga 2820
aaggggagtc tagaggggta gagtgtagac cacagggtga gtgagctgat tcgaggatgg 2880
ggagactggg agcccaccag tgaccagagc cagccctgtt cagggctgtc cgggcagaag 2940
aaagcagtgt cagacctgga atctgccatc agcacagcct gcaattgaca gacaagccca 3000
gagcaaagaa ggaagcactg cacatgagta agagcttgcc accagtgggg acagagtttc 3060
cagaattagg aaaataatca ctgggggcaa gtttgaggtt ggtaccagat atgtgggagg 3120
aggcaaggta agggaaagag tacttgaagt tggaactggt ccttgcaggg aaatgcacat 3180
ttatgaaacc ccgaaaactg atgtcaaagc acctcctgcc ttgggcagag tcctctcaga 3240
gtctacaggt gctgcctcca gaaccctctt cctggagcgc atccctatgt atctagaaat 3300
tctgctggga aatatgatgg tcagaccctt ggccacctga aaggttcagg gtggtagaag 3360
aaaaaggaaa gccacagggc agcaggggca ggtgccagca aggaaggcag gcacgccagg 3420
aagacaccca tggtgagaag tgcagatggc ccgagggcaa gtttgctcaa ctcacccagg 3480
tttgctcttg ctggggccaa gaggactcat gtgccagggc caagggccct tgggggctct 3540
cacagggggc ttatctgggc ttcggttctg gagggccagg aacaaacagg cttcaaagcc 3600
aagggcttgg ctggcacaca gggggcttgg tccttcacct ctgtcccctc tccctacgga 3660
cacatataag accctggtca cacctgggag aggaggagag gagagcatag cacctgccgc 3720
gg 3722
<210> 2
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
agtggtcttc gttccctgga ct 22
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
caagagacca catggcagga ag 22
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
gctttcccac cctcgcataa g 21
<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ttcactacaa aggctgagct ggag 24
<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ccataagaca ggtgctcctc cac 23
<210> 7
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
ttgaagcatt ccctaatgag ccac 24
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
ggctgttgcg cgggctccat 20
<210> 9
<211> 31
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
ttaaagttag tagcgtcgac cacgtgacta g 31
<210> 10
<211> 51
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
gcagcctgca cctgaggata atcgatctat aaccacgtga gaaagctttc t 51
<210> 11
<211> 46
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
tccacagcat gttcgagctc acgcctctcc agcctccctg cagctg 46
<210> 12
<211> 46
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
cagctgcagg gaggctggag aggcgtgagc tcgaacatgc tgtgga 46
<210> 13
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
atggagcccg cgcaacagcc gcc 23
<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
tcgactagag cttgcggaac cct 23
<210> 15
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
aagacaccag tttcagccca agttc 25
<210> 16
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
caagagacca catggcagga ag 22
<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
caaagctgaa agtcaagtct gcag 24
<210> 18
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
acccatggtg agaagtgcag atgg 24
<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
ctcttcaatg ccgtcatgaa atg 23
<210> 20
<211> 468
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
aaggcgatag aaggcgatgc gctgcgaatc gggagcggcg ataccgtaaa gcacgaggaa 60
gcggtcagcc cattcgccgc caagctcttc agcaatatca cgggtagcca acgctatgtc 120
ctgatagcgg tccgccacac ccagccggcc acagtcgatg aatccagaaa agcggccatt 180
ttccaccatg atattcggca agcaggcatc gccatgggtc acgacgagat catcgccgtc 240
gggcatgcgc gccttgagcc tggcgaacag ttcggctggc gcgagcccct gatgctcttc 300
gtccagatca tcctgatcga caagaccggc ttccatccga gtacgtgctc gctcgatgcg 360
atgtttcgct tggtggtcga atgggcaggt agccggatca agcgtatgca gccgccgcat 420
tgcatcagcc atgatggata ctttctcggc aggagcaagg tgagatga 468
Claims (6)
1. A method for constructing an idiopathic squamous cell carcinoma mouse model is characterized by comprising the following steps: (1) construction of mouse Yap1 with conditional Yap1 knockin Using the targeting vector for conditional Yap1 knockinKI(ii) a The conditional Yap1 knock-in targeting vector also comprises a negative selection marker DTA and a positive selection marker Neo;
the targeting vector for the conditional Yap1 knock-in takes KI431-basic vector as a basic vector, and also comprises a mouse mutant Yap1 gene, a human-derived SP-C promoter and a mouse ROSA26 gene which are connected in sequence; the nucleotide sequence of the SP-C promoter is shown as SEQ ID NO. 1; GenBank access number of mouse original Yap1 gene NM-001171147.1, Ensembl ENSMUSG 00000053110; GenBank access number of the ROSA26 gene is NR _027008.1, Ensembl is ENSMUSG 00000086429;
the construction method of the conditional Yap1 knock-in targeting vector comprises the following steps: (a) mutating a 112 th serine codon TCC of the original Yap1 gene coding of the mouse into an alanine codon GCC to obtain a mutated Yap1 gene;
(b) connecting an SP-C promoter from a Human with the mutant Yap1 gene in the step (a) to obtain a Human SP-C promoter-mutant mouse Yap1 CDS-ployA box;
(c) cloning the Human SP-C promoter-mutant mouse Yap1 CDS-ployA box obtained in the step (b) into an intron1 of ROSA26 in the opposite direction to obtain a Human SP-C promoter-mutant mouse Yap1 CDS;
(d) connecting the sequence of the Human SP-C promoter-mutant mouse Yap1 CDS obtained in the step (C) into a KpnI/PmlI enzyme cutting framework of the basic vector;
(2) crossing the mice with the conditional Yap1 knock-in gene with Trp53 knockout mice to obtain Yap1KI /Trp53KOA mouse.
2. The construction method according to claim 1, wherein the conditional Yap1 knock-in targeting vector is knocked into mouse blastocysts in step (1) by ES targeting.
3. The method for constructing a transgenic animal of claim 1, wherein the crossing of step (2) is performed by selecting the mouse Yap1 for conditional Yap1 knock-inKIThe homozygote of (2) and Trp53 knock-out mouse Trp53KOThe homozygotes were mated with cages.
4. The method of claim 3, wherein the pups obtained after mating with a cage are PCR validated.
5. The construction method according to claim 4, wherein the PCR-verified primers comprise primers Neo-del-F, Neo-del-R and WT-F for detecting Yap 1; primers Trp53-F1, Trp53-R1 and Trp53-F3 for detecting Trp 53;
the nucleotide sequence of the Neo-del-F is shown as SEQ ID NO.2, the nucleotide sequence of the Neo-del-R is shown as SEQ ID NO.3, and the nucleotide sequence of the WT-F is shown as SEQ ID NO. 7;
the nucleotide sequence of Trp53-F1 is shown as SEQ ID NO.4, the nucleotide sequence of Trp53-R1 is shown as SEQ ID NO.5, and the nucleotide sequence of Trp53-F3 is shown as SEQ ID NO. 6.
6. The construction method according to claim 5, wherein the PCR verification procedure comprises: the PCR program for detecting Tap1 by using primers Neo-del-F, Neo-del-R and WT-F comprises: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 64 ℃ for 35s, extension at 72 ℃ for 35s, and 33 cycles; extending for 5min at 72 ℃;
the PCR program for detecting Trp53 by using the primers Trp53-F1 and Trp53-R1 comprises the following steps: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 70 ℃ for 30s, and extension at 72 ℃ for 50s for 35 cycles; extending for 10min at 72 ℃;
the PCR program for detecting Trp53 by using the primers Trp53-F3 and Trp53-R1 comprises the following steps: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 30s, annealing at 70 ℃ for 30s, and extension at 72 ℃ for 50s, for 33 cycles; extension at 72 ℃ for 10 min.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010690583.0A CN111979265B (en) | 2020-07-17 | 2020-07-17 | Construction method of spontaneous squamous cell lung carcinoma mouse model |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010690583.0A CN111979265B (en) | 2020-07-17 | 2020-07-17 | Construction method of spontaneous squamous cell lung carcinoma mouse model |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111979265A CN111979265A (en) | 2020-11-24 |
CN111979265B true CN111979265B (en) | 2022-03-22 |
Family
ID=73438757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010690583.0A Active CN111979265B (en) | 2020-07-17 | 2020-07-17 | Construction method of spontaneous squamous cell lung carcinoma mouse model |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111979265B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110093369A (en) * | 2019-04-25 | 2019-08-06 | 成都药康生物科技有限公司 | A kind of construction method being overexpressed Yap1 genetic mouse model in the site H11 conditionity |
CN110923265A (en) * | 2019-12-19 | 2020-03-27 | 上海同科生物科技有限公司 | Construction method of mouse model for conditionally overexpressing HPV E7 gene at H11 site |
CN111019971A (en) * | 2019-12-19 | 2020-04-17 | 上海同科生物科技有限公司 | Construction method of mouse model for conditionally overexpressing HPV E6 gene at ROSA26 site |
CN111041047A (en) * | 2019-12-19 | 2020-04-21 | 上海同科生物科技有限公司 | Construction method of mouse model for conditionally site-specific double overexpression HPV E6/E7 gene |
-
2020
- 2020-07-17 CN CN202010690583.0A patent/CN111979265B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110093369A (en) * | 2019-04-25 | 2019-08-06 | 成都药康生物科技有限公司 | A kind of construction method being overexpressed Yap1 genetic mouse model in the site H11 conditionity |
CN110923265A (en) * | 2019-12-19 | 2020-03-27 | 上海同科生物科技有限公司 | Construction method of mouse model for conditionally overexpressing HPV E7 gene at H11 site |
CN111019971A (en) * | 2019-12-19 | 2020-04-17 | 上海同科生物科技有限公司 | Construction method of mouse model for conditionally overexpressing HPV E6 gene at ROSA26 site |
CN111041047A (en) * | 2019-12-19 | 2020-04-21 | 上海同科生物科技有限公司 | Construction method of mouse model for conditionally site-specific double overexpression HPV E6/E7 gene |
Non-Patent Citations (5)
Title |
---|
Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP;Qian Chen等;《Genes and Development》;20150615;第29卷(第12期);第1285-1297页,参见全文 * |
Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter;Kadoaki Ohashi等;《Cancer science》;20080628;第99卷(第9期);第1747-1753页,参见全文 * |
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma;Masaoki Ito等;《Cell Communication and Signaling》;20191228;第17卷(第1期);第137页,参见第1-11页 * |
The murine SP-C promoter directs type II cell-specific expression in transgenic mice;Stephan W Glasser等;《Am J Physiol Lung Cell Mol Physiol》;20041203;第288卷(第4期);第L625-632页,参见全文 * |
YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation;Hsinyi Huang等;《Cancer research》;20171101;第77卷(第21期);第5769-5781页,参见全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN111979265A (en) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6801030B2 (en) | Transgenic animals and how to use | |
CN108410911B (en) | LMNA gene knockout cell line constructed based on CRISPR/Cas9 technology | |
CN107815466B (en) | Preparation method and application of humanized gene modified animal model | |
CN107815468B (en) | Preparation method and application of humanized gene modified animal model | |
CN111733183B (en) | Targeting vector for constructing liver injury mouse model, nucleic acid composition and construction method | |
CN109197781B (en) | Construction method of AURKA-CKO1-N conditional gene knockout mouse model | |
CN111500628A (en) | Construction method and application of CD8 site-directed gene knock-in 2A-CreERT2-Wpre-pA mouse model | |
JP2023104002A (en) | Exon-humanized mouse | |
Pritchard et al. | Direct generation of conditional alleles using CRISPR/Cas9 in mouse zygotes | |
CN113801893A (en) | Construction method and application of Psme3 conditional gene knockout mouse model | |
CN107287236B (en) | Construction method of mouse model for human acute pancreatitis | |
Kang et al. | Apancreatic pigs cloned using Pdx1-disrupted fibroblasts created via TALEN-mediated mutagenesis | |
CN111979265B (en) | Construction method of spontaneous squamous cell lung carcinoma mouse model | |
CN113897369A (en) | Construction and application of KRT10 site-specific gene knock-in P2A-CrePR1-T2A-tdTomato mouse model | |
CN106544360B (en) | A method of terminating the transcription of lncRNA diallele | |
CN110547256B (en) | Method for breeding transgenic mice with specific knockout of lncRNA DLX6-os1 by kidney podocytes | |
Bouvier et al. | Recombineering‐based procedure for creating Cre/loxP conditional knockouts in the mouse | |
Higashitani et al. | Long-read sequence analysis of MMEJ-mediated CRISPR genome editing reveals complex on-target vector insertions that may escape standard PCR-based quality control | |
CN109504708A (en) | A kind of gene targeting carrier and method of self deletion of selection markers | |
JP4364474B2 (en) | Functional transposons in mammals | |
Gurumurthy et al. | CRISPR/Cas9 and the paradigm shift in mouse genome manipulation technologies | |
Brakebusch | Generation and analysis of genetically modified mice | |
CN113564205B (en) | Construction method of balanced chromosome animal model | |
CN111849977B (en) | Method for preparing transgenic animals by sperm vector, sgRNA for preparing short and small transgenic chickens and preparation method | |
US20060088898A1 (en) | Methods for the production of cells and mammals with desired genetic modifications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |